Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human fibrinogen concentrate - CSL Behring

Next Previous
Drug Profile

Human fibrinogen concentrate - CSL Behring

Alternative Names: Fibrinogen Concentrate (Human); Haemocomplettan P; RiaSTAP

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; Rigshospitalet
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Afibrinogenaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Afibrinogenaemia
  • Phase III Surgical blood loss
  • Phase II Haemorrhage

Most Recent Events

  • 28 Nov 2018 No recent reports of development identified for clinical-Phase-Unknown development in Haemorrhage(Adjunctive treatment) in United Kingdom (IV, Infusion)
  • 15 Jan 2018 Yale University and CSL Behring withdraws the PERFECT PPH phase I/II trial in Postpartum haemorrhage prior to enrolment, before January 2018 (NCT02528708)
  • 20 Apr 2017 CSL Behring completes a clinical trial in Haemorrhage (Adjunctive treatment) in United Kingdom (IV) (UKCRN19181)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top